Detalhe da pesquisa
1.
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Eur J Haematol
; 106(6): 808-820, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33638218
2.
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Future Oncol
; 15(31): 3531-3545, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31516032
3.
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Haematologica
; 108(12): 3454-3459, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439348
4.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
; 103(8): 1298-1307, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773593
5.
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Br J Haematol
; 172(1): 97-110, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26537529
6.
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Blood
; 123(9): 1309-18, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24345751
7.
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Am J Hematol
; 91(12): 1206-1214, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27531525
8.
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Am J Hematol
; 91(6): 606-16, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971533
9.
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Am J Hematol
; 90(9): 755-68, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26040495
10.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 346-7, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674873
11.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 348-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674874
12.
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Blood
; 119(15): 3403-12, 2012 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22371878
13.
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Am J Hematol
; 89(7): 732-42, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24711212
14.
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Leuk Res
; 139: 107481, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484432
15.
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood
; 118(17): 4567-76, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21865346
16.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Nat Med
; 29(9): 2259-2267, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37582952
17.
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Leukemia
; 36(7): 1825-1833, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643868
18.
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Curr Med Res Opin
; 37(5): 801-809, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33733983
19.
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomeâpositive leukemias.
Leuk Res
; 111: 106690, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34673442
20.
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Leukemia
; 34(8): 2125-2137, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32572189